zepbound mounjaro tirzepatide FDA approval for (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Eli Lilly to Spend $5.3

Important context: These are topline press release results peer-reviewed publication still awaited Retatrutide is investigational and not approved yet #obesitycare #retatrutide #mybestweight | My Best Weight

The prescribing information (SmPC) specifies the standard contraindications that apply across the EU: personal or family history of medullary thyroid carcinoma, MEN-2 syndrome, and prior serious hypersensitivity to tirzepatide

She own

Targeting the high-expression enzymes in cancer amino acid metabolism via small molecule inhibitors or RNAi-targeting approaches is emerging as a crucial therapy (Martinez-Outschoorn et al., 2017

Reassessing the role of GLP-1 in next-generation incretin-based obesity therapeutics